<DOC>
	<DOC>NCT01430013</DOC>
	<brief_summary>To evaluate the efficacy and safety of Endostar combined with CHOPT in the treatment of T cell lymphoma.</brief_summary>
	<brief_title>Trial of Endostar Combined With CHOPT for T Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<criteria>1. Male and female aged 18 to 70 years old. 2. Diagnosis of T cell lymphoma according to WHO Classification, without antitumor therapy 3. At least 1 measurable tumor mass (greater than 1.5cm in the longest dimension and greater than 1.0 in the short axis) 4. Eastern Cooperative Oncology Group status 02 5. White blood cell≥4.0×109cells/L; Absolute neutrophil count (ANC) ≥1.5×109cells /L; Platelets≥100×109cells/L 6. Alanine transaminase (ALT) ≤2×upper limit of normal(ULN); Aspartate transaminase (AST) ≤2×ULN; Total Bilirubin≤1.5×ULN; Creatinine in normal range 1. No active central nervous system lymphoma or brain tumor 2. Suppurative inflammation,Chronic infection 3. Severe heart disease, conclusion: congestive heart failure; uncontrolled cardiac arrhythmia; myocardial infarction; refractory hypertension 4. psychiatric history 5. Primary cutaneous T cell lymphoma 6. Pregnant or lactating women 7. Concurrent treatment with another investigational agent 8. Accept radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>